No Data
Target Price raised by 33%! JPMorgan is bullish on Contemporary Amperex Technology: technological innovation and global market expansion drive growth.
JPMorgan believes that due to the accelerated growth in sales, potential increases in unit economic efficiency, and its position as a CSI Leading Technology Index, the core competitive advantages of Contemporary Amperex Technology are promising. The target price has been significantly raised from 300 yuan to 400 yuan, indicating a potential increase of 53.9% compared to Tuesday's closing price.
Eoptolink Technology Inc. had an 80% increase in profits in Q4 last year compared to the previous quarter, but the details behind the investigation of the actual controller remain unclear.| Interpretations
① The demand for high-speed products is rapidly increasing, and Eoptolink Technology Inc. expects the net profit attributable to shareholders to grow over 300% year-on-year last year, with a quarter-on-quarter net profit increase of 47.76%-79.77% in Q4. ② Just a month ago, the actual controller, Gao Guangrong, was investigated by the Securities Regulatory Commission for allegedly violating restrictive regulations by transferring Stocks and other actions, and the details behind this remain unclear.
Cailian Press Autos Morning Report [January 16]
① The Ministry of Commerce: This week, detailed implementation rules for new purchase subsidies for mobile phones and other digital products will be issued successively; ② Guangdong: The production of New energy Fund vehicles will grow by 43% in 2024, accounting for a quarter of the national total; ③ Chongqing Changan Automobile: It will enter the Europe market in 2025;
Premium rate of 200%, valuation increased fivefold. Eve Energy Co., Ltd. intends to acquire employee-held subsidiary equity for 0.579 billion yuan ｜ Quick announcement read.
① Eve Energy Co.,Ltd. (300014.SZ) plans to acquire part of the equity of its subsidiaries held by the employee stock ownership platform for 0.579 billion yuan; ② A report by Caixin found that the employees spent 0.193 billion yuan to acquire this part of the equity that year, with a premium rate of 200%, but the valuation of the equity subsidiaries has increased fivefold compared to that year.
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
The "flying" pigs! Wens Foodstuff Group expects its revenue to surpass 100 billion yuan for the first time in 2024, with profits nearing 10 billion yuan | Quick announcement.
① Wens Foodstuff Group expects to achieve revenue exceeding 100 billion yuan and a net income of 9 billion-9.5 billion yuan in 2024; ② Analysts believe that the company's performance meets expectations but does not exceed them, which is considered normal; ③ In contrast to the impressive performance, Wens Foodstuff Group's stock price has dropped a cumulative 16.66% throughout the year 2024.
Daring Lu : China is the next Super power.